Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 0 1 427 3 5 15 2,114
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 0 295 1 1 5 1,324
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 0 8 850
Generic drug pricing in Canada: components of the value-chain 0 0 2 106 3 3 11 337
Microcredit in Pre-Famine Ireland 1 1 3 338 3 6 18 1,787
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 3 8 14 179
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 0 2 8 290
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 5 5 14 258
Subsidizing the Competition 0 0 0 134 2 3 7 689
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 0 324 2 2 9 1,598
Total Working Papers 1 1 6 1,894 22 35 109 9,426


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 0 1 547 4 4 11 4,122
A contractual approach to the gray market 0 0 0 123 1 4 10 417
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 0 0 0 0 1 3 12 16
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 0 2 7 7
Co-authorship and the output of academic economists 0 0 0 72 2 2 11 260
Competition policy in open economies 0 0 0 32 1 1 6 173
Der Green Impact Fund for Technology 0 0 0 3 0 3 10 23
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 2 3 6 24
Governance of electricity transmission systems 0 0 0 81 1 2 10 222
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 0 1 2 192 3 5 12 496
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 0 0 2 1 2 11 25
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 0 37 1 1 9 113
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 0 3 1 5 11 29
Microcredit in Prefamine Ireland 0 0 2 64 1 1 8 275
Microcredit: What can we learn from the past? 0 0 1 328 1 2 9 979
Microfinance and Famine: The Irish Loan Funds during the Great Famine 1 1 1 99 5 5 13 454
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 1 1 3 34 4 11 21 138
Patient income and health innovation 0 0 0 11 3 3 8 46
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 4 5 8 8
Preliminary Injunctions and Damage Rules in Patent Law 0 0 0 72 2 7 12 343
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 4 4 9 43
Strategic Implications of Learning by Doing 0 0 0 87 3 4 9 570
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 0 15 0 0 10 49
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 5 8 15 743
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 2 4 10 93
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 0 0 0 2 1 2 8 21
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 0 0 0 2 2 4 5
The importance of being first: evidence from Canadian generic pharmaceuticals 0 0 5 310 3 6 22 736
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 0 0 0 60 1 5 17 179
The life-cycle of a microfinance institution: the Irish loan funds 0 0 0 157 2 3 11 467
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 0 3 8 41
Total Journal Articles 2 3 15 2,599 61 112 328 11,117


Statistics updated 2026-05-06